Karmanos wins federal grant renewal for membership in Prostate Cancer Clinical Trials Consortium

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Barbara Ann Karmanos Cancer Institute has competed and been selected by scientific peers for a four-year grant renewal from the Department of Defense to continue membership in the prestigious Prostate Cancer Clinical Trials Consortium program.

Elisabeth Heath will direct Karmanos’ involvement in the consortium. Heath is leader of the Genitourinary Oncology Multidisciplinary Team, associate center director of Translational Sciences, and the Patricia C. and E. Jan Hartmann Endowed Chair for Prostate Cancer Research at Karmanos and Wayne State University School of Medicine.

The Prostate Cancer Clinical Consortium Award is a peer-reviewed, competitive grant. Peers include scientific researchers at universities and cancer centers across the nation. This year, only seven sites were funded, down from 11 sites in 2013.

Karmanos has been part of the consortium since 2008. The budget amount for the new four-year grant is $1.2 million. Heath’s co-principal investigator is Ulka Vaishampayan, director of the Eisenberg Center for Translational Therapeutics and co-investigators are Isaac Powell, and Lance Heilbrun, of Karmanos and WSU SOM.

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login